首页    期刊浏览 2024年11月09日 星期六
登录注册

文章基本信息

  • 标题:Treating cancer with phosphatidylinositol-3-kinase inhibitors: increasing efficacy and overcoming resistance
  • 本地全文:下载
  • 作者:Marcia N. Paddock ; Marcia N. Paddock ; Seth J. Field
  • 期刊名称:JLR Papers In Press
  • 印刷版ISSN:0022-2275
  • 电子版ISSN:1539-7262
  • 出版年度:2019
  • 卷号:60
  • 期号:4
  • 页码:747-752
  • DOI:10.1194/jlr.S092130
  • 出版社:American Society for Biochemistry and Molecular Biology
  • 摘要:The discovery of the phosphatidylinositol-3-kinase (PI3K) pathway was a major advance in understanding growth factor signaling. The high frequency of PI3K pathway mutations in many cancers has encouraged a new field targeting cancer driver mutations. Although there have been many successes, targeting PI3K itself has proven challenging, in part because of its multiple isoforms with distinct roles. Despite promising preclinical results, development of PI3K inhibitors as pharmacologic anticancer agents has been limited by modest single-agent efficacy and significant adverse effects. If we could overcome these limitations, PI3K inhibitors would be a powerful cancer-fighting tool. Data from phase III clinical trials yields insight into some of the problems with PI3K inhibitors. Recent advances have shed light on the mechanisms of tumor resistance to PI3K inhibitors via feedback pathways that cause elevated insulin levels that then activate the same PI3K pathways that are the targets of inhibition. Improving our understanding of the complex regulatory feedback pathways that activate in response to PI3K inhibition will reveal ways to increase the efficacy of PI3K inhibitors and reduce adverse effects, increasing the usefulness of this class as a treatment option for multiple cancer types.
  • 关键词:phosphoinositide ; insulin signaling ; insulin resistance ; phosphoinositides ; lipid kinases ; receptor tyrosine kinases ; signal transduction ; targeted therapies
国家哲学社会科学文献中心版权所有